Drug Trial Radar · NCT05414201
A Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Participants Requiring High Dose Corticosteroids for Active Non-Infectious Intermediate, Posterior, or Pan-Uveitis
Last checked: Nov 20, 2026Latest source record: Jun 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
87
Actual
Start
Jul 7, 2022
Primary completion
Jun 10, 2024
Study completion Jun 10, 2024
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Jun 10, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Non-infectious intermediate-, posterior- and pan-uveitis (NIIPPU) are sight threatening diseases with a high patient burden and negative impact on quality of life. Corticosteroids remain the mainstay of first-line treatment for NIIPPU in China despite serious side effects associated with long-term and high-dose corticosteroid use. Adalimumab is used to treat NIIPPU in adults who have had inadequate response to corticosteroids, or who need corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. The purpose of this study is to assess adverse events and effectiveness of adalimumab in Chinese participants requiring high dose corticosteroids with NIIPPU. Adalimumab is a conditionally approved drug in China used to treat participants with NIIPPU. All participants will receive the same treatment. Approximately 87 adult participants will be enrolled at approximately 15 sites in China. Participants will receive one subcutaneous loading dose of adalimumab at baseline followed a week later by a lower dose of adalimumab every other week for up to 30 weeks. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Conditions
- Non-infectious Intermediate Posterior- or Pan-uveitis
Interventions
AdalimumabDrug
Subcutaneous Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants that achieve quiescence in both eyesTime frame: Week 30
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Beijing Tongren Hospital, CMU /ID# 243054
Beijing, China
Tianjin Medical University Eye Hospital /ID# 243056
Tianjin, China
Xi'an people's hospital/Xi'an fourth hospital /ID# 243371
Xi'an, China
Peking University First Hospital /ID# 243055
Beijing, Beijing Municipality, China
Shanghai General hospital /ID# 247252
Shanghai, Shanghai Municipality, China
The second affiliated hospital of Zhejiang University school of medicine /ID# 247251
Hangzhou, Zhejiang, China
Eye hospital,WMU Zhejiang Eye Hospital /ID# 247253
Wenzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.